Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Operating Margin (2016 - 2023)

Spyre Therapeutics (SYRE) has disclosed Operating Margin for 7 consecutive years, with 23146.22% as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Operating Margin fell 1955854.0% year-over-year to 23146.22%, compared with a TTM value of 39428.92% through Mar 2024, down 3263528.0%, and an annual FY2023 reading of 27347.97%, down 2370774.0% over the prior year.
  • Operating Margin was 23146.22% for Q2 2023 at Spyre Therapeutics, down from 9497.98% in the prior quarter.
  • Across five years, Operating Margin topped out at 55.88% in Q2 2021 and bottomed at 23146.22% in Q2 2023.
  • Average Operating Margin over 3 years is 6777.45%, with a median of 3587.68% recorded in 2022.
  • The sharpest move saw Operating Margin tumbled -353180bps in 2022, then tumbled -1955854bps in 2023.
  • Year by year, Operating Margin stood at 560.98% in 2021, then tumbled by -1933bps to 11405.95% in 2022, then plummeted by -103bps to 23146.22% in 2023.
  • Business Quant data shows Operating Margin for SYRE at 23146.22% in Q2 2023, 9497.98% in Q1 2023, and 11405.95% in Q4 2022.